Prosecution Insights
Last updated: October 25, 2026

Fuller Ip Law LLC

Technology area: Biotechnology & Pharmaceuticals

72 pending office actions • 47 clients • 69 examiners • 53 art units • 0 of 72 (0%) have an AI response strategy ready

Analysis

FULLER IP LAW LLC has 73 pending office actions in Biotechnology & Pharmaceuticals. Its career record includes 771 applications, placing the current docket within an established historical practice.

The resolved allowance rate is 85.41%, and the average is 3.25 office actions per allowance. These figures give practitioners separate views of resolved outcomes and the examination interaction associated with allowed matters.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Quality Metrics (n=771 apps, methodology: how we score firms)

85.4%
Allowance Rate
n=771
+0.65σ
Allowance Rate (norm)
n=771
3.2
OAs to Allowance
n=322
-0.27σ
OAs to Allow (norm)
n=322
1046 days
Time to Allowance
n=322
+11.7pp
Interview Lift
n=771
29.7%
RCE Rate
n=771
0.8%
Appeal Rate
n=771

Rejection Performance (% of received rejections ultimately overcome)

56.9%
§101 Overcome
n=65
53.8%
§102 Overcome
n=186
55.0%
§103 Overcome
n=309
62.2%
§112 Overcome
n=275

Specialization & Scale

A61K, A61P, C12N
Top CPC Subclasses
32%
Top-3 CPC Share
n=771
2
Practitioners
n=771
385.5
Apps / Practitioner
n=771

Portfolio Summary

72
Total Pending OAs
43
Non-Final OAs
28
Final Rejections
1
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 13 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

9
Overdue
0
Due this week
3
Due this month
1
Due in next 60 days
0
Due later

Deadline Fire Line

Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 13 of the docket's apps have a known mailing date.

-30dToday30d60d90d120d
Overdue (9)Due ≤ 30 days (3)Due ≤ 60 days (1)

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

50
Hard (69%)
18
Medium (25%)
4
Easy (6%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
§101 + other7 (10%)
§103 only11 (15%)
§102 only2 (3%)
§112 only2 (3%)
Double-patenting only2 (3%)
Double-patenting + other5 (7%)
Multi-statute (no §101)43 (60%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

54
Life Sciences
75% of docket
2
Information Tech
3% of docket
1
Communications
1% of docket
5
Semiconductors
7% of docket
9
Mechanical / Eng
12% of docket
1
Business / Other
1% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

720 h
Manual time on pending OAs
144 h
Time saved (low, 20%)
252 h
Time saved (mid, 35%)
6.3 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
KAMM, JUDITH MARIE 2 42.9% +57.1%
BAUER, NICOLA MARIA 2 58.7% +52.1%
CLAUDIO VAZQUEZ, ADRIANA PAOLA 2 — —
AFREMOVA, VERA 1 50.5% +29.4%
JOHNSON, EMILY KATHARINE 1 87.5% +21.9%
FAN, WEIHUA 1 83.3% +12.7%
CORDOVA RODRIGUEZ, ULARISLAO 1 88.0% +13.6%
ZHENG, LI 1 83.5% +13.0%
RAHMAN, MASUDUR 1 72.9% +31.7%
AMARA, MOHAMED K 1 75.8% +29.7%

Hard Cases (50)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.

App #TitleExaminerDue in
18111875 Methods of Profiling Mass Spectral Data Using Neural Networks PHAM, TUAN A 98d overdue
18448685 ANTI-MICROBIAL ANTIBODY SIGNATURES OF INFLAMMATORY BOWEL DISEASE AND USES THEREOF GRASER, JENNIFER E 17d overdue
17045746 IMPROVED MANEUVERABILITY AERIAL VEHICLE AND A METHOD IMPLEMENTED FOR THIS PURPOSE GORDON, ANNA L 3d overdue
18570611 SUB-MICRON PARTICLE SHOMER, ISAAC 12d
18537982 SELF WARMING MEDICAL PRODUCTS, GELS, AND FLUIDS OUYANG, BO 33d
19424574 RAPID ISOLATION, CULTIVATION METHODS AND UTILITIES OF TRUFFLE FUNGI AFREMOVA, VERA —
19475770 PLANTS COMPRISING BROMOFORM PRODUCTION GENES JOHNSON, EMILY KATHARINE —
19125664 EPISTATIC TOMATO QTLS FOR INCREASING YIELD FAN, WEIHUA —

Interview Candidates (11)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.

App #TitleExaminerDue in
18041618 NANOPARTICULATE SYSTEM FOR TREATING ORAL CANCER KAMM, JUDITH MARIE 110d overdue
19424574 RAPID ISOLATION, CULTIVATION METHODS AND UTILITIES OF TRUFFLE FUNGI AFREMOVA, VERA —
19475770 PLANTS COMPRISING BROMOFORM PRODUCTION GENES JOHNSON, EMILY KATHARINE —
19125664 EPISTATIC TOMATO QTLS FOR INCREASING YIELD FAN, WEIHUA —
19190542 POWER CONVERTER CORDOVA RODRIGUEZ, ULARISLAO —
19169933 GENE EXPRESSION ELEMENTS AND SYSTEMS AND USE THEREOF ZHENG, LI —
18955955 POLYMORPHIC FORM OF MEISOINDIGO AND MODIFIED FORMULATION OF MEISOINDIGO KAMM, JUDITH MARIE —
18900613 CULTURED MEAT COMPOSITIONS RAHMAN, MASUDUR —

Client Portfolio (47 clients)

Top Art Units

Art UnitApps
16274
16623
16113
16783
16332
16122
36422
16362
16212
17982

Pending Office Actions

App #TitleClientExaminerArt UnitStatutesStatusDue inAIFiled
19424574 RAPID ISOLATION, CULTIVATION METHODS AND UTILITIES OF TRUFFLE FUNGI Black Boar Truffle, LLC AFREMOVA, VERA 1653 §102§103 Final Rejection — Pending Dec 18, 2025
19475770 PLANTS COMPRISING BROMOFORM PRODUCTION GENES Imi Tami Institute For Research & Development Ltd. JOHNSON, EMILY KATHARINE 1662 §103§112 Non-Final OA — Pending Oct 16, 2025
19125664 EPISTATIC TOMATO QTLS FOR INCREASING YIELD Yissum Research Development Company Of The Hebrew University Of Jerusalem Lt FAN, WEIHUA 1663 §101§112 Non-Final OA — Pending Apr 29, 2025
19190542 POWER CONVERTER Higher Wire, Inc. CORDOVA RODRIGUEZ, ULARISLAO 2838 §102§103 Non-Final OA — Pending Apr 25, 2025
19169933 GENE EXPRESSION ELEMENTS AND SYSTEMS AND USE THEREOF Geneneer Ltd. ZHENG, LI 1662 §103§112Other Non-Final OA — Pending Apr 03, 2025
18955955 POLYMORPHIC FORM OF MEISOINDIGO AND MODIFIED FORMULATION OF MEISOINDIGO Statia Biopharma Inc. KAMM, JUDITH MARIE 1611 §102§112Other Non-Final OA — Pending Nov 21, 2024
18900613 CULTURED MEAT COMPOSITIONS Aleph Farms Ltd. RAHMAN, MASUDUR 1633 §101§102§103§112 Non-Final OA — Pending Sep 27, 2024
18896776 TERRESTRIAL OBSERVING NETWORK FOR DIGITAL TWINS: REAL-TIME 3D MAPPING OF METRIC, SEMANTIC, TOPOLOGICAL, AND PHYSICOCHEMICAL PROPERTIES FOR OPTIMAL ENVIRONMENTAL MONITORING Desert Botanical Gardens AMARA, MOHAMED K 2877 §103 Final Rejection — Pending Sep 25, 2024
18850044 SYSTEM AND PROCESSES FOR CULTURING NON-HUMAN-ANIMAL CELLS UNDER VARIABLE GRAVITY CONDITIONS Aleph Farms Ltd. GU, QINHUA 1633 §103§112 Non-Final OA — Pending Sep 23, 2024
18886876 HIGH-ALTITUDE BALLOON PAYLOAD WITH ATTITUDE CONTROL AND PREDICTIVE SCHEDULING, FOR AEROBIOLOGICAL SAMPLING AND ENVIRONMENTAL MONITORING Arizona Board of Regents BLACK-CHILDRESS, RAJSHEED O 2685 §103 Final Rejection — Pending Sep 16, 2024
18839412 OCULAR SURGICAL MAGNET APPARATUS Emmetrope Ophthalmics LLC ACKUN, JACOB K 3736 §102§103 Non-Final OA — Pending Aug 16, 2024
18801052 METHOD OF TREATING OBESITY BY SELECTIVE TARGETING OF VISCERAL ADIPOSITY USING POLYCATION NANOMEDICINE The Trustees of Columbia University in the City of New York VIGIL, TORIANA NICHOLE 1612 §102§103§112 Final Rejection — Pending Aug 12, 2024
18837861 PLANT-BASED SKIN PREPARATIONS AND USE THEREOF Reagenics Research Ltd. DELEO, VICTORIA LYNN §102§103§112 Non-Final OA — Pending Aug 12, 2024
18836350 PREPARATION METHOD OF PYRIDAZINONE DERIVATIVE, AND INTERMEDIATE THEREOF Xizang Haisco Pharmaceutical Co., Ltd. PECKHAM, RICHARD GRANT 1627 §103§112 Non-Final OA — Pending Aug 06, 2024
18833879 PROPYLENE KETONE-CONTAINING BIOINHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF Jiangsu Hansoh Pharmaceutical Group Co., Ltd. WHITE, DAWANNA SHAR-DAY 1627 §102§103§112 Non-Final OA — Pending Jul 26, 2024
18778748 LOW-COST ROBOTIC SHAKE TABLE AND METHOD FOR OPERATING THE SAME University Of Nebraska-Lincoln SINHA, TARUN 2855 §102§103 Non-Final OA — Pending Jul 19, 2024
18730751 A TOMATO PLANT COMPRISING DOMINANT RESISTANCE GENES TO TOMATO BROWN RUGOSE FRUIT VIRUS Nrgene Technologies Ltd. BYRNES, DAVID R 1662 §101§112 Non-Final OA — Pending Jul 19, 2024
18723812 TRICYCLIC DERIVATIVE INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF Jiangsu Hansoh Pharmaceutical Group Co., Ltd. JACKSON, SHAWQUIA 1626 §102§112 Non-Final OA — Pending Jun 24, 2024
18744407 BATTERY-POWERED, TEMPERATURE-CONTROLLED DEVICES AND METHODS FOR TRANSPORT, STORAGE, AND EXPERIMENTATION IN MICRO-GRAVITY RESEARCH AND MANUFACTURING APPLICATIONS Ambassador Asset Management Limited Partnership BONZELL, PHILIP J 3642 §102§103 Non-Final OA — Pending Jun 14, 2024
18719257 PYRIMIDINE OR PYRIDINE DERIVATIVE AND MEDICINAL USE THEREOF Signet Therapeutics Inc. REILLY, SOPHIA JANE 1627 §102§103§112 Non-Final OA — Pending Jun 12, 2024
18717414 ECO-FRIENDLY METHOD, APPARATUS, AND SYSTEM FOR PRECIPITATION AND COLLECTION OF DISSOLVED SUPPORT MATERIAL Oryx Additive, Inc. GURTOWSKI, RICHARD C 1773 §102§103 Non-Final OA — Pending Jun 06, 2024
18661485 SOLID OXIDE FUEL CELLS WITH 3D INKJET-PRINTED MICROSTRUCTURES AND METHOD FOR FABRICATING THE SAME Arizona Board of Regents SMITH, JEREMIAH R 1723 §102§103 Non-Final OA — Pending May 10, 2024
18700664 COMPOSITE INK FORMULATIONS FOR ENDOSCOPIC IMAGING Mayo Foundation for Medical Education and Research DONOHUE, SEAN R 1618 §102§103§112 Non-Final OA — Pending Apr 11, 2024
18699189 COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER The Translational Genomics Research Institute RAO, PADMAJA S 1627 §103§112 Non-Final OA — Pending Apr 05, 2024
18622162 METHOD FOR MODULATING UNPRODUCTIVE ALTERNATIVE SPLICING The Trustees of Columbia University in the City of New York HUDSON, AMY ROSE 1636 §102§103§112 Non-Final OA — Pending Mar 29, 2024
18622705 MNO NANOMATERIAL BASED INHIBITORS OF INFLAMMATION AND CANCER METASTASIS Newsouth Innovations Pty Ltd SCHLIENTZ, NATHAN W 1616 §102§103§112 Non-Final OA — Pending Mar 29, 2024
18696937 APPARATUS AND METHOD FOR THERMAL PROCESSING Renergi Pty Ltd. MALLON, BRETT PETERSON 3762 §102§103§112 Non-Final OA — Pending Mar 28, 2024
18692247 METHOD FOR FABRICATING LAYERED SORBENT FILMS USING ADHESIVE Arizona Board of Regents GHORISHI, SEYED BEHROOZ 1748 §103 Final Rejection 3d overdue Pending Mar 14, 2024
18685883 AROMATIC RING-CONTAINING BIOLOGICAL ANTAGONIST, AND PREPARATION METHOD THEREFOR AND USE THEREOF Jiangsu Hansoh Pharmaceutical Group Co., Ltd. BAUER, NICOLA MARIA 1621 §102§103 Non-Final OA — Pending Feb 22, 2024
18682111 APPLICATION OF STEROID COMPOUND IN PREPARATION OF DRUG FOR PREVENTING AND/OR TREATING EYE FLOATERS Ocusun Ophthalmic Pharmaceutical (Guangzhou) Co., Ltd. ARCORIA, PAUL JOSEPH 1621 §103 Final Rejection — Pending Feb 07, 2024
18291209 SAMPLE EXTRACTION DEVICE Guangzhou National Laboratory RAMIREZ, ALEX 1798 §102§103§112 Non-Final OA — Pending Jan 22, 2024
18415537 ANTIMICROBIAL SOLUTIONS AND USES THEREOF Ecoplanet Environmental LLC MORNHINWEG, JEFFREY P 1793 §102§103 Non-Final OA — Pending Jan 17, 2024
18570611 SUB-MICRON PARTICLE Imperial College Innovations Limited SHOMER, ISAAC 1612 §102§103 Final Rejection 12d Pending Dec 14, 2023
18537982 SELF WARMING MEDICAL PRODUCTS, GELS, AND FLUIDS Ldc Business Consulting LLC OUYANG, BO 3794 §102§103 Non-Final OA 33d Pending Dec 13, 2023
18525163 VIBRATING ANESTHESIA DEVICE Superior Dermatology Solutions LLC GRASMEDER, SARAH DYMPNA 3783 §103 Final Rejection — Pending Nov 30, 2023
18556737 ANALYSIS OF FRAGMENT ENDS IN DNA Wisconsin Alumni Research Foundation WOITACH, JOSEPH T 1687 §101§103 Non-Final OA — Pending Oct 23, 2023
18491581 RIGID ENDOTRACHEAL INTUBATION STYLET Sam Rx, Pllc DITMER, KATHRYN ELIZABETH 3785 §102§103 Non-Final OA — Pending Oct 20, 2023
18554199 THERAPEUTIC MODALITIES FOR INHIBITING PANCREATIC BETA CELL IMPAIRMENT AND TREATING DIABETES Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. HABTE, KAHSAY 1624 §102 Final Rejection — Pending Oct 05, 2023
18480489 TEMPORAL TRAUMATIC BRAIN INJURY BIOMARKERS AND METHODS OF USE THEREOF Arizona Board of Regents NGUYEN, NAM P 1678 §112DP Final Rejection 43d overdue Pending Oct 03, 2023
18552892 ORGANIC COMPOUNDS, ORGANIC ELECTROLUMINESCENT DEVICE AND ELECTRONIC APPARATUS Shaanxi Lighte Optoelectronics Material Co., Ltd. CLAUDIO VAZQUEZ, ADRIANA PAOLA 1789 §103 Non-Final OA — Pending Sep 27, 2023
18551863 NITROGEN-CONTAINING COMPOUND, ORGANIC ELECTROLUMINESCENT DEVICE, AND ELECTRONIC APPARATUS Shaanxi Lighte Optoelectronics Material Co., Ltd. CLAUDIO VAZQUEZ, ADRIANA PAOLA 2899 §103§112Other Non-Final OA — Pending Sep 21, 2023
18551356 METHODS AND COMPOUNDS FOR NEOANTIGEN VACCINES The Translational Genomics Research Institute JOHANSEN, PETER N. 1644 §102§103 Non-Final OA — Pending Sep 19, 2023
18464846 COMPOSITIONS AND METHODS OF USE OF SYNTHETIC PEPTIDES WITH MYCOBACTERIUM ABSCESSUS INHIBITORY ACTIVITY Arizona Board of Regents BUNKER, AMY M 1684 DP Final Rejection — Pending Sep 11, 2023
18448685 ANTI-MICROBIAL ANTIBODY SIGNATURES OF INFLAMMATORY BOWEL DISEASE AND USES THEREOF Mayo Foundation for Medical Education and Research GRASER, JENNIFER E 1645 §101§102§112 Final Rejection 17d overdue Pending Aug 11, 2023
18362678 IDENTIFICATION AND ISOLATION OF HUMAN CORNEAL ENDOTHELIAL CELLS (HCECS) Emmecell, Inc. GABEL, GAILENE 1678 §102§112Other Non-Final OA — Pending Jul 31, 2023
18261475 CRYSTALLIZATION OF HIGH-PURITY MAGNESIUM L-LACTATE Triplew Ltd. KELLY-O'NEILL, YOLANDA LYNNETTE 1692 §103 Final Rejection 11d overdue Pending Jul 13, 2023
18350089 METHODS AND FORMULATIONS FOR PRENATAL TREATMENT OF ALLAN-HERNDON-DUDLEY SYNDROME The University of Chicago LEE, ANDREW P 1691 §103DP Non-Final OA — Pending Jul 11, 2023
18254153 IMPROVING COGNITIVE FUNCTION Dalhousie University MARLEN, TAMMIE K 3796 §102§103 Non-Final OA — Pending May 23, 2023
18316806 SYSTEM AND METHOD OF FOUNDATION REPAIR DIAGNOSTICS AND REMEDIATION DESIGN Arizona Foundation Solutions, LLC TRAN, SCOTT THANH BINH 2186 §101§103§112 Non-Final OA — Pending May 12, 2023
18251222 A MULTI-SCAFFOLD SYSTEM FOR LARGE SCALE CULTIVATION OF CELLS Aleph Farms Ltd. MCGUIRK, JOHN SCHUYLER 1798 §103 Final Rejection 12d Pending Apr 28, 2023

View all 72 →

Managing Fuller Ip Law LLC's Patent Prosecution?

IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Frequently Asked Questions

What is Fuller Ip Law LLC's patent allowance rate?

85.4% of resolved applications prosecuted by Fuller Ip Law LLC were allowed, across 771 applications in USPTO records.

How many office actions does Fuller Ip Law LLC average before allowance?

3.25 office actions per allowed application on average.

How many pending office actions does Fuller Ip Law LLC have?

72 pending office actions as of October 2026, for 47 clients, before 69 examiners in 53 art units.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month